Get ahead of the ACHE: Monoclonal Antibodies in Migraine Prevention
|
|
- Sophie Garrison
- 5 years ago
- Views:
Transcription
1 Get ahead of the ACHE: Monoclonal Antibodies in Migraine Prevention Amanda Janisch, PharmD PGY2 Ambulatory Care Pharmacy Resident MCHS SWMN, Mankato, MN 2018 MFMER slide-1
2 Disclosures No financial interest or conflicts of interest to disclose Discussion of off-label use for the following in migraine prevention: metoprolol, atenolol, amitriptyline, venlafaxine, lisinopril, candesartan, carbamazepine, clonidine, and guanfacine 2018 MFMER slide-2
3 Objectives Explain the pathophysiology and epidemiology of migraines Describe treatment guidelines for management of migraines Discuss novel monoclonal antibodies for migraine prevention 2018 MFMER slide-3
4 Definitions Headache- head pain without neurologic symptoms Migraine- head pain with neurologic symptoms such as aura, nausea, vomiting, aversion to light, sound, or smell Episodic migraine (EM)- headache 14 days/month Chronic migraine (CM)- headache >15 days/month for at least 3 months, with 8 migraine days/month Katsarava Z. Curr Pain Headache Rep MFMER slide-4
5 Epidemiology Migraine affects ~14% of the population More common in women Highest prevalence in age range of 40 to 49 Associated cost >$13 billion Loss in productivity Studies suggest that ~30% of patients with migraine need preventative therapy 3-13% use preventative therapy AAN/AHS. Am Fam Physician Katsarava Z. Curr Pain Headache Rep MFMER slide-5
6 Pathophysiology COMPLEX Activation & sensitization of trigeminovascular pathways Dysregulation of sensory processing leading to neurologic symptoms Associations Comorbidities: depression, anxiety, chronic pain disorders Medication over-use Environmental factors: caffeine use, stress Katsarava Z. Curr Pain Headache Rep MFMER slide-6
7 TRUE or FALSE Chronic Migraine (CM) occurs more commonly than Episodic Migraine (EM) MFMER slide-7
8 a. True b. False 2018 MFMER slide-8
9 Patient Case MK a 42 year old female, is diagnosed with EM. PMH: hypertension and s/p kidney excision (donor) She currently takes sumatriptan 50 mg as needed and is using more frequently (~8x/month) Other medications include: losartan and oral contraceptive 2018 MFMER slide-9
10 Acute Treatment Non-Steroidal Anti-inflammatory (NSAIDs) 1 st line for mild-moderate migraines Triptans 1 st line for moderate-severe migraines Dopamine antagonist antiemetics 2 nd line for migraine treatment Refractory Migraines May use parenteral dihydroergotamine, magnesium sulfate, valproate, and opioids Mayans L, et al. Am Fam Physician MFMER slide-10
11 Preventative Therapy Consider when: 2 migraine days per month with disability lasting 3 days/month Acute treatment failure, adverse effects, or contraindication Use of abortive therapy 2 times/week Patient preference and cost Goals: Reduce frequency, intensity, and duration Modi S, et al. Am Fam Physician MFMER slide-11
12 FDA Approved for Migraine Prevention Medication divalproex (Depakote ) topiramate (Topamax ) propranolol (Inderal ) Level of evidence A: 2 Class I trials OnabotulinumtoxinA (Botox ) Dosage Range IR: 250 mg twice daily up to 1000 mg/day ER: 500 mg-1000 mg/day IR: 25 mg-100 mg in two divided doses ER: 25 mg-100 mg once daily IR: 80 mg/day divided every 6-8 hours, maximum of mg/day ER: 80 mg once daily initially, Effective range mg once daily 5 units/0.1 ml per site with total dose of 155 units divided between 31 IM sites every 12 weeks. Silberstein SD,et al. Neurology MFMER slide-12
13 Off-label use for Migraine Prevention Medication Dosage Range Level of Evidence metoprolol (Lopressor, n/a A Toprol XL ) atenolol (Tenormin ) n/a B amitriptyline (Elavil ) 10 mg-150 mg daily B venlafaxine (Effexor ) ER: 37.5 mg- 150 mg daily B Silberstein SD,et al. Neurology Micromedex Database MFMER slide-13
14 Off-label use for Migraine Prevention Medication lisinopril (Zestril, Prinivil ) candesartan (Atacand ) carbamazepine (Tegretol ) clonidine (Catapres ) guanfacine (Tenex, Intuniv ) Level of Evidence C C C C C Silberstein SD,et al. Neurology MFMER slide-14
15 NOT Recommended or Effective for Migraine Prevention lamotrigine (Lamictal ) clomipramine (Anafranil ) clonazepam (Klonopin ) nabumetone (Relafen ) oxcarbazepine (Trileptal ) telmisartan (Micardis ) Silberstein SD,et al. Neurology MFMER slide-15
16 Drug Induced Headache Overuse of acute headache medications (>10 days/month) Butalbital products, acetaminophen, caffeine, NSAIDs, codeine, triptans Stimulants Hormone therapy Nitrates Mayo Clinic MFMER slide-16
17 Patient Case Which of the following products should NOT be recommended for MK as a first-line agent for migraine prevention? 2018 MFMER slide-17
18 a. topiramate b. butalbital/acetaminophen/caffeine c. propranolol d. divalproex 2018 MFMER slide-18
19 Erenumab-aooe (Aimovig ) Approval Approved 5/17/2018 for EM and CM prevention Mechanism Monoclonal antibody Binds to calcitonin gene-related peptide (CGRP) receptor Product 70 mg monthly Sub-Q injection Cost: $ /carton of two SureClick Autoinjectors (8 week supply) Lauritsen CG, Silberstein SD. Pract Neurology DailyMed GoodRx 2018 MFMER slide-19
20 Erenumab-aooe Properties 4 letter abbreviation- naming convention for biologic agents Fully Human monoclonal antibody ~90% human derived, ~10% murine IgG2 type antibody 2018 MFMER slide-20
21 Calcitonin Gene-Related Peptide (CGRP) Pathway CGRP serum levels increase during migraine attack Trigeminal nerve stimulation increases CGRP CGRP concentration correlates to headache intensity Edvinsson L. Headache MFMER slide-21
22 Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study Ashina M, Tepper S, Brandes JL, et al. Cephalalgia MFMER slide-22
23 Objectives Primary Endpoint: Change from baseline in monthly migraine days (MMD) Secondary Endpoints: Achievement of 50% and 75% reduction from baseline in MMD Change from baseline in monthly acute migraine-specific medication days (MSMD) based on use of acute medications (triptans/ergots) Ashina M., et al. Cephalalgia MFMER slide-23
24 Study Methods Multicenter, randomized, double-blind, placebocontrolled, 12-week, parallel-group study Subgroup analysis in CM placebo erenumab 70 mg monthly erenumab 140 mg monthly Ashina M., et al. Cephalalgia MFMER slide-24
25 Enrollment Inclusion Exclusion Adult patients with CM ( 15 headache days/month; 8 migraine days/month) No therapeutic response to >3 preventative treatment categories Ashina M., et al. Cephalalgia MFMER slide-25
26 Subgroup Baseline Characteristics Characteristic Placebo n= 286 Erenumab 70 mg n= 191 Erenumab 140 mg n= 190 Age, years Female, % MMD Monthly MSMD MMD- Monthly Migraine Days MSMD- Migraine-Specific Medication Days Ashina M., et al. Cephalalgia MFMER slide-26
27 Change in MMD Results 50% reduction in MMD No Prior Treatment 1 Prior Treatment Failure 2 Prior Treatment Failure 70 mg 140mg 70mg 140mg 70mg 140mg -2.2 (-4.1, -0.3)* 1.8 (0.9, 3.4) -0.5 (-2.4, 1.5) 1.3 (0.7, 2.7) -2.5 (-3.8, -1.2)** 2.6** (1.6, 4.5) -3.3 (-4.6, -2.1)** 3.3** (2.0, 5.5) -2.7 (-4.2, -1.2)** 3.5** (1.8, 6.6) -4.3 (-5.8, -2.8)** 4.2** (2.2, 7.9) 75% reduction in MMD 2.0 (0.8, 4.8) 1.9 (0.8, 4.6) 3.1* (1.2, 10.9) 4.6** (2.1, 10.0) 3.6* (1.2, 10.9) 8.0** (2.8, 23.0) **p<0.001 *p<0.05 treatment groups compared to placebo Ashina M., et al. Cephalalgia MFMER slide-27
28 Results 38.1 Proportion of Patients Reaching 50% Reduction in MMD over 3 Months No Prior Treatment >1 Prior Treatment Failure >2 Prior Treatment Failures Placebo Erenumab 70mg Erenumab 140mg Ashina M., et al. Cephalalgia MFMER slide-28
29 Results Proportion of Patients Reaching 75% Reduction in MMD over 3 Months No Prior Treatment Failure > 1 Prior Treatment Failure >2 Prior Treatment Failures Placebo Erenumab 70mg Erenumab 140mg Ashina M., et al. Cephalalgia MFMER slide-29
30 Strengths 1 st trial to evaluate erenumab in CM in patients with prior preventative treatment failures Limitations Subgroup analysis Not powered to detect differences within each subgroup Statistical testing was not pre-specified or adjusted for multiplicity Exclusion criteria limited patients with higher treatment failures Ashina M., et al. Cephalalgia MFMER slide-30
31 Conclusions Erenumab was effective and well tolerated in patients with previous treatment failures Further studies need for long-term safety/ efficacy and in patients exhibiting no therapeutic response to >3 classes of preventative therapy MFMER slide-31
32 Treatment with erenumab resulted in 50% reduction in monthly migraine days in CM for ~ % of patients MFMER slide-32
33 a % b % c % d % 2018 MFMER slide-33
34 ARISE: A Phase 3 randomized trial of erenumab for episodic migraine Dodick DW, Ashina M, Brandes JL, et al. Cephalalgia MFMER slide-34
35 Objectives Primary Endpoint: Change in monthly migraine days (MMD) Secondary Endpoints: 50% reduction in monthly migraine days (MMD) Change in acute migraine-specific medication treatment days (MSMD) 5-point reduction in Physical Impairment and Impact on Everyday Activities domain scores measured by the Migraine Physical Function Impact Diary (MPFID) Dodick DW, et al. Cephalalgia MFMER slide-35
36 Migraine Physical Function Impact Diary (MPFID) 13 item patient reported outcome measure Demonstrated reliability and validity in two domains in prospective, observational study Not used in clinical practice Developed by Amgen Inc. Kawata AK, et al. Headache MFMER slide-36
37 Study Methods Multicenter, randomized, double-blind, placebocontrolled, parallel-group, phase 3 trial Randomized 1:1 to placebo or erenumab 70 mg monthly subcutaneous injection 577 patients randomized Dodick DW, et al. Cephalalgia MFMER slide-37
38 Enrollment Inclusion Exclusion Adults with EM ( 4 to 15 MMD and <15 headache days per month) History of no therapeutic response to >2 preventative medication classes Use of preventative medications during trial (washout period required) Dodick DW, et al. Cephalalgia MFMER slide-38
39 Baseline Characteristics Characteristic Placebo n= 291 Erenumab 70 mg n= 286 Age, years 42 ±12 42 ± 11 Female sex, no (%) 247 (84.9) 245 (85.7) Age at migraine onset 22 ± ± 10 Prior Prophylactic Therapy, no (%) 125 (43) 123 (43) No Previous Prophylactic Therapy, no 174 (59.8) 178 (62.2) (%) MMD 8.4 ± ± 2.7 MSMD 3.4 ± ± 3.6 MPFID impact on everyday activities 13.2 ± ± 8.6 score MPFID physical impairment score 11.5 ± ± 9.1 MMD- Monthly Migraine Days MSMD- Migraine-Specific Medication Days Dodick DW, et al. Cephalalgia MFMER slide-39
40 Results Endpoint Placebo Erenumab 70 mg Change in MMD -1.8 days -2.9 days -1.0 (-1.6, -0.5) p< 0.001* 50% reduction in MMD 29.5% 39.7% OR: 1.59, (1.12,2.27) p=0.01* Change in MSMD -0.6 days -1.2 days OR: -0.6, (-1.0,-0.2) p=0.002* MPFID impact on everyday activities score ( 5-point reduction) MPFID physical impairment score ( 5-point reduction) * statistically significant MMD- Monthly Migraine Days 35.8% 40.4% OR: 1.22, (0.87, 1.71) p= % 33.0% OR: 1.33, (0.92, 1.90) p=0.13 Dodick DW, et al. Cephalalgia MFMER slide-40
41 Strengths Endpoints measured Limitations Excluded patients on preventative treatment Dodick DW, et al. Cephalalgia MFMER slide-41
42 Conclusion Erenumab reduced MMD and MSMD in patients with EM Further studies in combination with other migraine preventative treatments and in cardiovascular disease 2018 MFMER slide-42
43 Safety Adverse effects similar between treatment and placebo groups within both studies Common Adverse Effects ( 2%) injection site pain sinusitis influenza upper respiratory fatigue tract infection (URI) nausea nasopharyngitis constipation 2018 MFMER slide-43
44 Place in Therapy- Erenumab-aooe (Aimovig ) May be appropriate for patients with CM or EM that have had prior treatment failures Cost will likely limit use until more market competition Reports of prior authorization and restricted prescribing 2018 MFMER slide-44
45 Patient Case MK established care with a neurologist after failing an adequate trial of divalproex, nortriptyline, and gabapentin. She developed flank pain with topiramate. Which of the following is an appropriate option for this patient? 2018 MFMER slide-45
46 a. erenumab (Aimovig ) b. onabotulinumtoxina (Botox ) c. propranolol (Inderal ) d. all of the above 2018 MFMER slide-46
47 Future Considerations with CGRP Antagonists fremanezumab Phase III trials completed eptinezumab Phase II trials completed ubrogepant (oral) Phase III trial underway for acute treatment atogepant (oral) Under development for prevention glacanezumab Phase II trials completed telcagepant & MK-3207 Trials stopped due to hepatotoxicity Tso AR, Goadsby PJ. Curr Treat Options Neurol MFMER slide-47
48 Summary Migraine preventative medications are often underutilized First-line agents include divalproex, topiramate, propranolol, and onabotulinumtoxina CGRP antagonists will likely find a place in treatment after patients have failed multiple first-line agents 2018 MFMER slide-48
49 Questions 2018 MFMER slide-49
1/25/2018 ARE CGRP ANTAGONISTS ANY BETTER THAN CURRENT EVIDENCE BASED TREATMENTS? Disclosures: Objectives: Headache Division
ARE CGRP ANTAGONISTS ANY BETTER THAN CURRENT EVIDENCE BASED TREATMENTS? Lawrence C Newman, MD, FAHS, FAAN Clinical Professor of Neurology Disclosures: Advisory Board: Alder, Allergan, Amgen, Lilly, Supernus,
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
CGRP Page 1 of 13 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: CGRP (calcitonin gene-related peptide) Prime Therapeutics will review Prior Authorization requests
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
CGRP Page 1 of 8 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: CGRP (calcitonin gene-related peptide) Prime Therapeutics will review Prior Authorization requests
More information10/19/2018. Disclosures MIGRAINE PROPHYLAXIS. Objectives. Definitions Slide. What do you think the aooe stands for at the end of erenumab-aooe?
Disclosures MIGRAINE PROPHYLAXIS Erenumab-aooe (AIMOVIG TM ) Calcitonin Gene Related Peptide Receptor Antagonist No conflicts of interest to disclose Chelsey Roscoe, PharmD PGY1 Resident - CTVHCS 2 3 Definitions
More informationSubject: Aimovig (erenumab) Original Effective Date: 7/10/2018. Policy Number: MCP-320. Revision Date(s):
Subject: Aimovig (erenumab) Original Effective Date: 7/10/2018 Policy Number: MCP-320 Revision Date(s): Review Date(s): MCPC Approval Date: 7/10/2018 DISCLAIMER This Molina Clinical Policy (MCP) is intended
More informationPage: 1 of 6. Aimovig (erenumab-aooe) injection, Ajovy (fremanezumab-vfrm) injection, Emgality (galcanezumab-gnim)
Page: 1 of 6 Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Last Review Date: November 30, 2018 Description Aimovig (erenumab-aooe) injection, Ajovy (fremanezumab-vfrm)
More informationCGRP, MONOCLONAL ANTIBODIES AND SMALL MOLECULES (-GEPANTS)
CGRP, MONOCLONAL ANTIBODIES AND SMALL MOLECULES (-GEPANTS) Hans-Christoph Diener Senior Professor of Clinical Neurosciences University Duisburg-Essen Germany CGRP, Monoclonal Antibodies and Small Molecules
More information10/17/2017 CHRONIC MIGRAINES BOTOX: TO INJECT OR NOT INJECT? IN CHRONIC MIGRAINE PROPHYLAXIS OBJECTIVES PATIENT CASE EPIDEMIOLOGY EPIDEMIOLOGY
BOTOX: TO INJECT OR NOT INJECT? IN CHRONIC MIGRAINE PROPHYLAXIS OBJECTIVES JENNIFER SHIN, PHARMD PGY2 AMBULATORY CARE PHARMACY RESIDENT COMMUNITYCARE HEALTH CENTERS PHARMACOTHERAPY ROUNDS OCTOBER 20, 2017
More informationPreventive treatment of migraine. Rebecca Burch, MD Brigham and Women s Faulkner Hospital Harvard Medical School Boston, MA
Preventive treatment of migraine Rebecca Burch, MD Brigham and Women s Faulkner Hospital Harvard Medical School Boston, MA No disclosures Disclosures Many preventive treatments for migraine are not FDA-approved
More informationAdvances in the Treatment of Migraine
Advances in the Treatment of Migraine C. Philip O Carroll, M.D. Director Neurobehavioral Medicine Hoag Neurosciences Institute Guyuron B Headache, 2015;55:1464-1473 I m sorry your head hurts, sweetie.is
More informationClinical Learning Days November 10, 2017
Migraine Clinical Learning Days November 10, 2017 Alyssa Lettich. MD Neurosciences Institute/Neurosciences Clinical Program Medical Director Headache Disclosures: none Learning Objectives: At the conclusion
More informationHeadache A Practical Approach
Headache A Practical Approach Integrated Pain Symposium December 1, 2017 Alyssa Lettich. MD Neurosciences Institute/Neurosciences Clinical Program Medical Director Headache and Pain Development Teams Disclosures:
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Aimovig) Reference Number: CP.PHAR.128 Effective Date: 07.10.18 Last Review Date: 08.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationSubject: CGRP Inhibitors
ARCHIVED (NOT ACTIVE RETIRED) Archived: 08/01/18 09-J2000-98 Original Effective Date: 06/15/18 Reviewed: 05/09/18 Revised: 08/01/18 Next Review: ARCHIVED (NOT ACTIVE RETIRED) Subject: CGRP Inhibitors THIS
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Emgality) Reference Number: CP.PHAR.## Effective Date: 11.13.18 Last Review Date: 02.19 Line of Business: Commercial, TBD HIM*, Medicaid Revision Log See Important Reminder at the end
More informationOTE. Aimovig : A Novel Therapy for Preventive Treatment of Migraine. Vol. 34, Issue 3 December Established 1985
HAR Vol. 34, Issue 3 December 2018 M A N OTE Established 1985 Aimovig : A Novel Therapy for reventive Treatment of Migraine Michelle Vanderhoof, harmd Candidate I n the Global Burden of Disease Study 2015,
More informationProposed Project Scope. OPTIMAL USE OnabotulinumtoxinA for the Prevention of Chronic Migraine Clinical Evidence, Policies and Practice
Proposed Project Scope OPTIMAL USE OnabotulinumtoxinA for the Prevention of Chronic Migraine Clinical Evidence, Policies and Practice May 2018 1. BACKGROUND AND RATIONALE Migraine is a common, debilitating
More informationClinical case. Clinical case 3/15/2018 OVERVIEW. Refractory headaches and update on novel treatment. Refractory headache.
OVERVIEW Refractory headaches and update on novel treatment Definition of refractory headache Treatment approach Medications Neuromodulation In the pipeline Juliette Preston, MD OHSU Headache Center Refractory
More informationHMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in
HMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in Anesthesia and Neurology Harvard Medical School Limited time
More informationADVANCES IN MIGRAINE MANAGEMENT
ADVANCES IN MIGRAINE MANAGEMENT Joanna Girard Katzman, M.D.MSPH Assistant Professor, Dept. of Neurology Project ECHO, Chronic Pain Program University of New Mexico Outline Migraine throughout the decades
More informationARxCH. Annual Review of Changes in Healthcare. Calcitonin Gene-Related Peptide Receptors and the Prevention of Migraines. Abstract
Calcitonin Gene-Related Peptide Receptors and the Prevention of Migraines Brian Schuler, PharmD Candidate 2018 1 1 University of Findlay College of Pharmacy Abstract Migraines are the third most prevalent
More informationDaniel Kassicieh, DO, FAAN
Daniel Kassicieh, DO, FAAN Migraine a Disease Process Migraine is a chronic disease process similar to many other chronic medical conditions Migraine has a low mortality but high morbidity 38 million Americans
More information10/13/17. Christy M. Jackson, MD Director, Dalessio Headache Center Scripps Clinic, La Jolla Clinical Professor, Neurosciences UCSD
Christy M. Jackson, MD Director, Dalessio Headache Center Scripps Clinic, La Jolla Clinical Professor, Neurosciences UCSD } Depomed Consultant 2014 to present } Avanir Consultant 2014 to present } Amgen
More informationA New Class of Drugs for Migraine Prevention: Calcitonin Gene-Related Peptide (CGRP)- Directed Treatments
A New Class of Drugs for Migraine Prevention: Calcitonin Gene-Related Peptide (CGRP)- Directed Treatments Samantha Otto-Meyer, PharmD Clinical Instructor PGY1 Community Pharmacy Resident Marlowe Djuric
More informationWhat is new in the migraine world! Modar Khalil Consultant neurologist Hull Royal Infirmary
What is new in the migraine world! Modar Khalil Consultant neurologist Hull Royal Infirmary Overview Understanding the burden Commonly used terms Acute therapy What we currently have What we are going
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Ajovy) Reference Number: CP.PHAR.## Effective Date: 10.30.18 Last Review Date: 02.19 Line of Business: Commercial, TBD HIM*, Medicaid Revision Log See Important Reminder at the end of
More informationStrategies in Migraine Care
Strategies in Migraine Care Julie L. Roth, MD Rhode Island Hospital Assistant Professor, Neurology The Warren Alpert Medical School of Brown University March 28, 2015 Financial Disclosures None. Objectives
More informationABORTIVE AGENTS. Average cost per 30 days. Form Limits SEROTONIN AGONISTS $ $ Reserved for treatment failure to either Sumatriptan PA; QL
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Migraine Therapy P&T DATE: 12/11/2018 CLASS: Neurological Disorders REVIEW HISTORY 9/17, 12/16, 9/15, 2/15, 2/10, LOB: MCL
More informationPROMISE 2 Top-Line Data Results January 8, 2018
PROMISE 2 Top-Line Data Results January 8, 2018 Forward-Looking Statements This presentation and the accompanying commentary contains certain forward-looking statements within the meaning of Section 27A
More informationDISCLOSURE OBJECTIVES
A New Class of Drugs for Migraine Prevention: Calcitonin Gene-Related Peptide (CGRP)- Directed Treatments Samantha Otto-Meyer, PharmD Clinical Instructor PGY1 Community Pharmacy Resident DISCLOSURE Dr.
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Goadsby PJ, Reuter U, Hallström Y, et al. A controlled trial
More informationLost in Translation: Making Sense of Clinical Treatment Guidelines
Lost in Translation: Making Sense of Clinical Treatment Guidelines Charles E. Argoff, MD, CPE Disclosures: Charles Argoff Financial Disclosure: Consultant: Teva, Daiichi Sakyo, Pfizer, Nektar, Purdue,
More informationA Controlled Trial of Erenumab for Episodic Migraine
The new england journal of medicine Original Article A Controlled Trial of Erenumab for Episodic Migraine Peter J. Goadsby, M.D., Ph.D., Uwe Reuter, M.D., Yngve Hallström, M.D., Gregor Broessner, M.D.,
More informationUpdate on Diagnosis and Management of Migraines
Update on Diagnosis and Management of Migraines Joel J. Heidelbaugh, MD, FAAFP, FACG Clinical Professor Departments of Family Medicine and Urology University of Michigan Learning Objectives To distinguish
More informationCGRP, MABs and Small Molecules. David W. Dodick, M.D. Professor Department of Neurology Mayo Clinic Phoenix Arizona
CGRP, MABs and Small Molecules David W. Dodick, M.D. Professor Department of Neurology Mayo Clinic Phoenix Arizona Disclosure Consulting: Allergan, Amgen, Alder, eneura, Colucid, Trigemina, Eli Lilly &
More informationMIGRAINE UPDATE. Objectives & Disclosures. Learn techniques used to diagnose headaches. Become familiar with medications used for headache treatment.
MIGRAINE UPDATE Karen L. Bremer, MD November 16, 2018 Objectives & Disclosures Learn techniques used to diagnose headaches. Become familiar with medications used for headache treatment. Disclosure: I am
More informationClinical Policy: Sumatriptan Reference Number: CP.CPA.260 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: Reference Number: CP.CPA.260 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationChronic Migraine in Primary Care. December 11 th, 2017 Werner J. Becker University of Calgary
Chronic Migraine in Primary Care December 11 th, 2017 Werner J. Becker University of Calgary Disclosures Faculty: Werner J. Becker Relationships with commercial interests: Grants/Research Support: Clinical
More informationHow do we treat migraine? New SIGN Guidelines
How do we treat migraine? New SIGN Guidelines Managing your migraine Migraine Trust, Edinburgh 2018 Callum Duncan Consultant Neurologist Aberdeen Royal Infirmary Chair SIGN Guideline 155 Premonitory Mood
More informationCalcitonin Gene-Related Peptide (CGRP) Inhibitors as Preventive Treatments for Patients with Episodic or Chronic Migraine: Effectiveness and Value
Calcitonin Gene-Related Peptide (CGRP) Inhibitors as Preventive Treatments for Patients with Episodic or Chronic Migraine: Effectiveness and Value Background Draft Background and Scope December 4, 2017
More informationI have no financial relationships to disclose. I will not discuss investigational use of medication in my presentation.
I have no financial relationships to disclose. I will not discuss investigational use of medication in my presentation. In 1962, Bille published landmark epidemiologic survey of headache among 9,000 school
More informationWhat is the Effectiveness of OnabotulinumtoxinA (Botox ) in Reducing the Number of Chronic Migraines (CM) in Patients Years Old?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2013 What is the Effectiveness of OnabotulinumtoxinA
More informationNovartis announces Phase III STRIVE data published in NEJM demonstrating significant and sustained efficacy of erenumab in migraine prevention
Novartis International AG Novartis Global Communications CH-4002 Basel Switzerland http://www.novartis.com MEDIA RELEASE COMMUNIQUE AUX MEDIAS MEDIENMITTEILUNG Novartis announces Phase III STRIVE data
More informationCommitted to Transforming the Treatment Paradigm for Migraine Prevention
Committed to Transforming the Treatment Paradigm for Migraine Prevention 36th Annual J.P. Morgan Healthcare Conference January 8, 2018 Forward-Looking Statements This presentation and the accompanying
More informationMigraine Migraine Age Specific Prevalence in the United States. Headache International Headache Society Classification
28 Primary Care Medicine Principles and Practice 29 October 28 Professor Peter J. Goadsby Peter.Goadsby@headache.ucsf.edu Department of Neurology Headache International Headache Society Classification
More informationMy patient s pain in the head, is a pain in Greg Jicha, M.D., Ph.D.
My patient s pain in the head, is a pain in the @%$*&# Greg Jicha, M.D., Ph.D. Kentucky Neurologic Institute University of Kentucky, Lexington, KY Migraine is More Common than Asthma & Diabetes Combined
More informationCurrent Migraine Treatment Therapy. Daniel Kassicieh, DO, FAAN
Current Migraine Treatment Therapy Daniel Kassicieh, DO, FAAN Migraine a Disease Process Migraines are a chronic disease process similar to many other chronic medical conditions Migraine has a low mortality
More informationMigraine Management. Roger Cady, MD Headache Care Center Springfield, MO
Migraine Management Roger Cady, MD Headache Care Center Springfield, MO Disclosures Objectives The evolution of migraine From benign episodic (benign) headache to potentially a devastating chronic disease
More informationGoals. Primary Headache Syndromes. One-Year Prevalence of Common Headache Disorders
Goals One-Year Prevalence of Common Headache Disorders Impact of primary headache syndromes Non pharmacologic Rx of migraine individualized to patient triggers Complementary and alternative Rx of migraine
More informationClinical Policy: Sumatriptan Reference Number: CP.HNMC.260 Effective Date: Last Review Date: Line of Business: Medicaid Medi-Cal
Clinical Policy: Reference Number: CP.HNMC.260 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy for important
More informationMigraine - whats on the horizon
Managing your migraine Edinburgh Saturday 10 th March 2018 Migraine - whats on the horizon Alok Tyagi Consultant Neurologist Glasgow Disclaimer I have received from Janssen Cillag, GSK, Allergan, Electrocore,
More informationMigraine Controversies in Women s Health. Professor Peter J. Goadsby 5 December Department of Neurology
Migraine 2008 Controversies in Women s Health 5 December 2008 Professor Peter J. Goadsby Peter.Goadsby@headache.ucsf.edu Department of Neurology Headache International Headache Society Classification Primary
More informationCOLUMBIA UNIVERSITY HEADACHE CENTER: NEW PATIENT QUESTIONNAIRE
COLUMBIA UNIVERSITY HEADACHE CENTER: NEW PATIENT QUESTIONNAIRE HEADACHE CHARACTERISTICS Frequency and Severity 1. At what AGE did you get your first headache, of ANY kind? 2. At what AGE did your headaches
More informationRegulatory Status FDA approved indication: Migranal Nasal Spray is indicated for the acute treatment of migraine headaches with or without aura (1).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.60 Subject: Migranal Nasal Spray Page: 1 of 5 Last Review Date: November 30, 2018 Migranal Nasal Spray
More informationTriptans Quantity Limit Program Summary
Triptans Quantity Limit Program Summary FDA APPROVED INDICATIONS AND DOSAGE 1-13,14,23,24 Agents Amerge (naratriptan) 1, 2.5 tablets Axert (almotriptan) 6.25, 12.5 tablets migraine attacks with/without
More informationPrednisone vs. placebo in withdrawal therapy following medication overuse headache
doi:10.1111/j.1468-2982.2007.01488.x Prednisone vs. placebo in withdrawal therapy following medication overuse headache L Pageler 1,2, Z Katsarava 2, HC Diener 2 & V Limmroth 1,2 1 Department of Neurology,
More informationMigraine Management. Dr Helen Brown Director of Neurology and Stroke The Princess Alexandra Hospital
Migraine Management Dr Helen Brown Director of Neurology and Stroke The Princess Alexandra Hospital Referral Criteria for Migraine Migraine Management Migraine Diagnosis Spot on Health Migraine pathway
More informationRichard B. Lipton, 1 Joel Saper, 2 Messoud Ashina, 3 David Biondi, 4 Suman Bhattacharya, 4 Joe Hirman, 5 Barbara Schaeffler, 4 Roger Cady 4
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of for the Preventive Treatment of Chronic Migraine: Results of the PROMISE-2 (PRevention Of Migraine via
More informationDisclosures. Triptans for Kids 5/16/13
5/16/13 Disclosures Triptans for Kids Amy A. Gelfand, MD GelfandA@neuropeds.ucsf.edu Departments of Neurology and Pediatrics UCSF Child Neurology and Headache Center I receive grant funding from: NIH/NINDS
More informationFaculty Disclosures. Learning Objectives. Acute Treatment Strategies
WWW.AMERICANHEADACHESOCIETY.ORG Acute Treatment Strategies Content developed by: Lawrence C. Newman, MD, FAHS Donna Gutterman, PharmD Faculty Disclosures LAWRENCE C. NEWMAN, MD, FAHS Dr. Newman has received
More informationEmerging drugs for migraine treatment: an update
Expert Opinion on Emerging Drugs ISSN: 1472-8214 (Print) 1744-7623 (Online) Journal homepage: http://www.tandfonline.com/loi/iemd20 Emerging drugs for migraine : an update Giorgio Lambru, Anna P. Andreou,
More informationTreatment Of Medication. Overuse Headache
7 November 2012 BASH GPwSI Meeting Lecture title... Treatment Of Medication Dr... Overuse Headache Dr Marcus Lewis Dr... The National Migraine Centre International Headache Society Diagnostic criteria
More informationCalcitonin Gene Related Peptide Receptor Inhibitors Prior Authorization Criteria:
Request for Prior Authorization for Calcitonin Gene Related Peptide Receptor Inhibitors Website Form www.highmarkhealthoptions.com Submit request via: Fax - 1-855-476-4158 All requests for Calcitonin Gene
More informationTABLE 1. Current Diagnostic Criteria for Migraine Without Aura 2 A. At least 5 attacks fulfilling criteria B-D B. Headache attacks lasting 4-72 hours
ANSWERS CONCISE TO FREQUENTLY REVIEW ASKED QUESTIONS FOR CLINICIANS ABOUT MIGRAINE Answers to Frequently Asked Questions About Migraine IVAN GARZA, MD, AND JERRY W. SWANSON, MD Migraine is a common primary
More informationManagement options for Migraine. Prof. Dr. Khwaja Nazimuddin Head Dept. of Internal Medicine BIRDEM
Management options for Migraine Prof. Dr. Khwaja Nazimuddin Head Dept. of Internal Medicine BIRDEM Assessment The Migraine Disability Assessment Score MIDAS Complete loss of work Partial loss of work Off
More informationMEASURE #3: PREVENTIVE MIGRAINE MEDICATION PRESCRIBED Headache
MEASURE #3: PREVENTIVE MIGRAINE MEDICATION PRESCRIBED Headache Measure Description Percentage of patients age 18 years old and older diagnosed with migraine headache whose migraine frequency is 4 migraine
More information2017 Eli Lilly and Company
Galcanezumab (LY2951742) CGRP Monoclonal Antibody for the Prevention of Migraine: Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies, ART01 and CGAB This information is provided in response
More informationPrevention and Treatment of Migraines CAITLIN BARNES, PHARM.D. CANDIDATE AMBULATORY CARE JOE CAMMILLERI, PHARM.D. NATOHYA MALLORY, PHARM.D.
Prevention and Treatment of Migraines CAITLIN BARNES, PHARM.D. CANDIDATE AMBULATORY CARE JOE CAMMILLERI, PHARM.D. NATOHYA MALLORY, PHARM.D. Objectives Present patient case Review epidemiology/pathophysiology
More informationAnti-Calcitonin Gene-Related Peptide Monoclonal Antibodies: Adverse Effects. What Do We Really Know? A Literature Review
Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies: Adverse Effects. What Do We Really Know? A Literature Review Authors: Theodoros Mavridis, 1,2 Chrysa Koniari, 1,2 Nikolaos Fakas, 2 *Dimos D.
More informationClinical Policy: Triptans Reference Number: CP.CPA.217 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: Reference Number: CP.CPA.217 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationZomig. Zomig / Zomig-ZMT (zolmitriptan) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.22 Subject: Zomig Page: 1 of 5 Last Review Date: November 30, 2018 Zomig Description Zomig / Zomig-ZMT
More informationManaging Migraine: Primary Care for Primary Headaches
Managing Migraine: Primary Care for Primary Headaches Faculty Jeffrey Unger, MD, FAAFP, FACE Director, Unger Primary Care Concierge Medical Group, Rancho Cucamonga, California; Director of Metabolic Studies,
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
Generic Brand HICL GCN Exception/Other ONABOTULINUMTOXINA BOTOX 04867 BRAND BOTOX COSMETIC ABOBOTULINUMTOXINA DYSPORT 36477 RIMABOTULINUMTOXINB MYOBLOC 21869 INCOBOTULINUMTOXINA XEOMIN 36687 Please use
More informationMark W. Green, MD, FAAN
Mark W. Green, MD, FAAN Professor of Neurology, Anesthesiology, and Rehabilitation Medicine Director of Headache and Pain Medicine Icahn School of Medicine at Mt Sinai New York Pain-sensitive structures
More informationNothing to disclose 3
Nothing to disclose 3 PREVALENCE AND BURDEN OF HEADACHE Patient with CDH IHS migraine Recurrent severe headache Severe headache Episodic headache Have had headache Entire population CDH=chronic daily headache.
More informationIndex. Prim Care Clin Office Pract 31 (2004) Note: Page numbers of article titles are in boldface type.
Prim Care Clin Office Pract 31 (2004) 441 447 Index Note: Page numbers of article titles are in boldface type. A Abscess, brain, headache in, 388 Acetaminophen for migraine, 406 407 headache from, 369
More informationMigraine Management. Jane Melling Headache nurse Mater Misericordiae Hospital
Migraine Management Jane Melling Headache nurse Mater Misericordiae Hospital Migraine facts Among the most common disorders of the nervous system 3 rd most prevalent medical disorder on the planet (lancet
More informationCOMBINATION THERAPIES PREVENTATIVE THERAPIES BETA BLOCKERS
ACUTE THEAPIES TIPTANS TICYCLIC ANTIDEPESSANTS When starting acute treatment, healthcare professionals should warn patients about the risk of developing medication-overuse headache. ASPIIN Aspirin (900
More informationHEADACHE PATHOPHYSIOLOGY
HEADACHE PATHOPHYSIOLOGY Andrew Charles, M.D. Professor Director, UCLA Goldberg Migraine Program Meyer and Renee Luskin Chair in Migraine and Headache Studies Director, Headache Research and Treatment
More informationAdult with headache. Problem-specific video guides to diagnosing patients and helping them with management and prevention
Adult with headache Problem-specific video guides to diagnosing patients and helping them with management and prevention London Strategic Clinical Networks London Neuroscience Strategic Clinical Network
More informationSchedule FDA & literature based indications
Psychotropic Medication List Recommended dosages are intended to serve only as a guide for children. Recommended doses are literature based. Clinicians should consult package insert of medications for
More informationCommitted to Transforming the Treatment Paradigm for Migraine Prevention
June 14, 2018 Committed to Transforming the Treatment Paradigm for Migraine Prevention September 6, 2018 Forward-Looking Statements This presentation and the accompanying commentary contains certain forward-looking
More informationปวดศ รษะมา 5 ป ก นยาแก ปวดก ย งไม ข น นพ.พาว ฒ เมฆว ช ย โรงพยาบาลนครราชส มา
ปวดศ รษะมา 5 ป ก นยาแก ปวดก ย งไม ข น นพ.พาว ฒ เมฆว ช ย โรงพยาบาลนครราชส มา 1 CONTENT 1 2 3 Chronic Daily Headache Medical Overused Headache Management Headaches are one of the most common symptoms List
More informationUPDATE IN MIGRAINE MANAGEMENT
UPDATE IN MIGRAINE MANAGEMENT Eric P. Baron, DO Cleveland Clinic Neurological Institute Center for Neurological Restoration Headache and Chronic Pain Medicine barone2@ccf.org @Neuralgroover Disclosures
More informationEmerging Challenges in Primary Care: Brainstorm: A Symposium on Migraine Treatment and Management
Emerging Challenges in Primary Care: 2017 Brainstorm: A Symposium on Migraine Treatment and Management 1 Faculty Jeff Unger, MD, ABFM, FACE Director, Unger Primary Care Medical Group Rancho Cucamonga,
More informationAbortive Agents. Available Strengths. Formulary Limits. Tablet: 5mg, 10mg ODT: 5mg, 10 mg 25mg, 50mg, 100mg. 5mg/act, 20mg/act
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Migraine Therapy P&T DATE: 9/12/2017 CLASS: Neurological Disorders REVIEW HISTORY 12/16, 9/15, 2/15, 2/10, 5/07 LOB: MCL
More informationOCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA
OMED 17 OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA 29.5 Category 1-A CME credits anticipated ACOFP / AOA s 122 nd Annual Osteopathic Medical Conference & Exposition Joint Session with ACOFP, ACONP and AOAAM:
More informationChange Your Brain, Change Your Life. The Breakthrough Program for Conquering Anxiety, Depression, Obsessiveness, Anger, and Impulsiveness
Change Your Brain, Change Your Life The Breakthrough Program for Conquering Anxiety, Depression, Obsessiveness, Anger, and Impulsiveness Daniel G Amen Three Rivers Press New York Appendix Medication 1.
More information10/19/12. Headache: Tips and Tools for Management. Michael A. Rogawski, MD, PhD Disclosures
10/19/12 Headache: Tips and Tools for Management Michael A. Rogawski, MD, PhD University of California, Davis Sacramento, CA Michael A. Rogawski, MD, PhD Disclosures Grants: Congressionally Directed Medical
More information1. On how many days in the last 3 months did you miss work or school because of your headaches?
The Migraine Disability Assessment Test The MIDAS (Migraine Disability Assessment) questionnaire was put together to help you measure the impact your headaches have on your life. The information on this
More informationClinical Policy: Triptans Reference Number: CP.HNMC.217 Effective Date: Last Review Date: Line of Business: Medicaid Medi-Cal
Clinical Policy: Reference Number: CP.HNMC.217 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy for important
More informationONZETRA XSAIL (sumatriptan) nasal powder
ONZETRA XSAIL (sumatriptan) nasal powder Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationA New Era of Migraine Management: The Challenging Landscape in Prevention
Provided by MediCom Worldwide, Inc. Supported by an educational grant from Teva Pharmaceuticals What is a Neuropeptide? Small chains of amino acids released by neural cells (neurons or glial cells) to
More information6/2/2017. Objectives. Statement of Problem: Migraine Headaches Are Common. Chronic Headache In Pediatrics, Botox and Beyond
Chronic Headache In Pediatrics, Botox and Beyond Ken Mack MD PhD Mayo Clinic 2015 MFMER slide-1 Objectives Understand pediatric chronic headache presentations Review evidence for the treatment of chronic
More informationSingle Technology Appraisal (STA) Erenumab for preventing migraine ID1188
Single Technology Appraisal (STA) Erenumab for preventing migraine ID1188 Comment 1: the draft remit Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Appropriateness
More informationMIGRAINE PROPHYLAXIS. Julie Cromer, Pharm.D. Candidate
Volume 22, Issue 4 January 2007 MIGRAINE PROPHYLAXIS Julie Cromer, Pharm.D. Candidate Migraine is a chronic, debilitating neurological disorder with major implications on patient quality of life. As estimated
More informationAtenolol in the prophylaxis of chronic migraine: a 3-month open-label study
Edvardsson SpringerPlus 2013, 2:479 a SpringerOpen Journal RESEARCH Open Access Atenolol in the prophylaxis of chronic migraine: a 3-month open-label study Bengt Edvardsson Abstract Background: Chronic
More information